Elixirgen and Nippon Shinyaku Partner to Advance Full-Length Dystrophin mRNA Therapy EXG-7001 for Duchenne Muscular Dystrophy

Elixirgen Therapeutics has signed an option agreement with Nippon Shinyaku Co., Ltd. to develop EXG-7001, an investigational messenger RNA (mRNA) therapy for Duchenne muscular dystrophy (DMD). Under the agreement, Elixirgen will lead clinical development of the candidate, while Nippon Shinyaku will fund development costs and retain the option to obtain exclusive worldwide commercialization rights.

The collaboration strengthens the development pathway for EXG-7001, a preclinical full-length dystrophin mRNA therapy that aims to address one of the major limitations of current DMD treatments. If Nippon Shinyaku exercises its option and the therapy receives U.S. regulatory approval, commercialization will be handled by NS Pharma, Inc., the company’s wholly owned U.S. subsidiary.

Under the terms of the agreement, Elixirgen will receive an upfront payment and will be eligible for additional milestone payments tied to clinical development and future commercial sales.

Full-Length Dystrophin mRNA Therapy Targets the Root Cause of DMD

EXG-7001 is a locally administered mRNA therapeutic intended to produce the complete, full-length dystrophin protein that is absent or defective in patients with DMD. Unlike exon-skipping therapies and micro-dystrophin gene replacement approaches, which restore only shortened versions of dystrophin and often benefit specific genetic mutations, EXG-7001 has the potential to deliver the entire dystrophin protein regardless of the underlying mutation.

By restoring full-length dystrophin, the therapy could improve muscle cell stability and function across a broader population of patients with DMD if clinical studies confirm its safety and efficacy.

Development Program Remains in the Preclinical Stage

EXG-7001 is currently in preclinical development, and no human efficacy or safety data have been reported. Clinical trial timelines have not yet been disclosed.

The agreement allows Elixirgen to continue advancing the program with financial support from Nippon Shinyaku while leveraging the Japanese rare disease company’s global commercialization expertise if development progresses successfully.

Addressing a Significant Unmet Need in Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a rare, progressive X-linked neuromuscular disorder caused by mutations in the DMD gene that result in the absence or dysfunction of dystrophin, a structural protein essential for maintaining healthy muscle fibers. The disease causes progressive muscle weakness, loss of mobility, respiratory decline, cardiomyopathy, and premature mortality.

Although several disease-modifying therapies have become available in recent years, many provide mutation-specific benefits or produce shortened dystrophin proteins, leaving a substantial unmet need for treatments capable of restoring normal dystrophin expression across a wider patient population.

Commenting on the partnership, Elixirgen Chief Executive Officer Aki Ko said current DMD therapies primarily restore incomplete dystrophin proteins, while EXG-7001 has the potential to deliver the full-length protein missing in patients regardless of their specific genetic mutation. Ko added that the collaboration combines Elixirgen’s clinical and regulatory capabilities with Nippon Shinyaku’s long-standing commitment to rare disease therapies.

Path Forward

The partnership positions EXG-7001 for continued preclinical advancement toward first-in-human clinical evaluation. As development progresses, Nippon Shinyaku may exercise its option to secure exclusive worldwide commercialization rights. Following potential U.S. regulatory approval, NS Pharma will lead marketing and commercialization activities in the United States, expanding Nippon Shinyaku’s growing portfolio of therapies for rare neuromuscular diseases.

Reference

Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy • Elixirgen Therapeutics